Quick answerThe drug is stopped for good, and the provider selects the replacement.
Why this is correctAngioedema is a bradykinin-mediated class effect rather than a dose-related one, so a smaller dose carries the same risk. A recurrence can involve the airway, which makes rechallenge unsafe.
Easy analogy or mental pictureIt is an allergy-style exit from the whole class, not a speed adjustment. The comparison conveys permanence while leaving the substitute choice to the prescriber.
Memory hookACE inhibitor angioedema ends the class, not just the dose.NCLEX decision ruleAfter ACE inhibitor angioedema, the drug is discontinued and not rechallenged. Any substitute, including an angiotensin receptor blocker, is a prescribing decision made with the provider.
Why the other choices are wrongDose reduction, self-starting a substitute, and premedication all keep the client exposed to a reaction that can involve the airway.